First clinical data from ongoing Phase 1 dose escalation trial (APEX-01) shows a prostate-specific antigen (PSA) decrease of > 50% reduction in PSA levels from baseline in 3 of 3 patients with metastatic prostate cancer receiving ARX517 at 2.0 mg/kg (Cohort 6)
2 of 3 patients in Cohort 6 experienced a greater than 90% reduction in PSA levels
No drug-related severe adverse events (SAEs) or dose limiting toxicities (DLTs) have been observed
These data provide early evidence of proof of concept for single-agent ARX517 as an ADC treatment for advanced prostate cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.